OGI Bio, a Scottish biotechnology company, has secured follow-on funding of £650,000 in a deal led by TRICAPITAL Angels and supported by Scottish Enterprise, Merleview, Apollo, and Old College Capital to accelerate the company’s growth and expansion in the UK, EU, and US biotechnology sectors.

Specialising in developing innovative solutions for microbial growth and analysis, OBI Bio focuses on creating advances bioreactors and automated systems that enhance the efficiency and precision of microbial growth.

By integrating cutting-edge technology and automation, OGI Bio facilitates product development in fields such as health and beauty, food manufacturing, feedstock, and green alternatives to petrochemicals.

The company’s solutions aim to optimise microbial workflows, reduce labour costs, and increase reproducibility from the earliest stages of product development.

OGI Bio was founded to overcome the challenges of time-consuming manual microbial growth. Unable to afford expensive automation solutions, the founders created and built their own systems from scratch.

“With this investment, we will be launching additional modules to complement our existing market offerings and an enhanced software package that provides our customers with greater flexibility in process control. This will allow them to view, measure, and control their culturing processes from anywhere in the world.” said Alex McVey, CEO of OGI Bio.

Recommended reading

• UK Gov Invests Millions Into Medtech Devices for Future NHS Use
• Scottish Health Board Testing AI for Lung Disease Treatment
• Scots Uni Researchers Develop Swallowable Medtech Sensor

“TRICAPITAL Angels has been a crucial partner for OGI Bio since March 2022, leading the company’s first pre-seed raise alongside partners, including long-term backers Apollo Informal Investments. Over the past two years, TRICAPITAL Angels has continued to provide unwavering support, participating in two further financing rounds.“ McVey added.